Generation of 20 human induced pluripotent stem cell lines from patients with focal segmental glomerulosclerosis (FSGS)

Cernoch, Janine; Fisch, Tanja; Fischer, Iris; Fischer, Kristin; Iwanska, Anna; Krüger, Norman; Küchler, Judit; Schaar, Claudia; Schommer, Sandra; Telugu, Narasimha; Miller, Duncan C.; Vallone, Valeria Fernández; Kurtz, Armin; Reinke, Petra; Diecke, Sebastian; Stachelscheid, Harald

doi:10.1016/j.scr.2021.102406

Cited by 2 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…hiPSC-DSNs were differentiated from the established stem cell line BIHi005-A ( https://hpscreg.eu/cell-line/BIHi005-A, Berlin Institute of Health Stem Cell Core Facility), obtained by reprogramming of human dermal fibroblasts using Sendai viral vectors as previously reported ( 32 , 33 ). After approval by the Charité ethics committee (ClinicalTrials.gov NCT02753036) and written informed consent had been obtained, 2 additional hiPSC lines from 2 patients with breast cancer were reprogrammed from PBMCs using Sendai viral vectors (cell lines BIHi264-A and BIHi263-A, Berlin Institute of Health Stem Cell Core Facility), using established protocols ( 34 ). iPSCs were tested for the absence of the reprogramming vector, with immunofluorescence staining for pluripotency markers, in vitro directed differentiation into the 3 germ layers, karyotyping using SNP arrays, and g banding, as described previously ( 34 ) and in detail in another study ( 32 ).…”

Section: Methodsmentioning

confidence: 99%

“…After approval by the Charité ethics committee (ClinicalTrials.gov NCT02753036) and written informed consent had been obtained, 2 additional hiPSC lines from 2 patients with breast cancer were reprogrammed from PBMCs using Sendai viral vectors (cell lines BIHi264-A and BIHi263-A, Berlin Institute of Health Stem Cell Core Facility), using established protocols ( 34 ). iPSCs were tested for the absence of the reprogramming vector, with immunofluorescence staining for pluripotency markers, in vitro directed differentiation into the 3 germ layers, karyotyping using SNP arrays, and g banding, as described previously ( 34 ) and in detail in another study ( 32 ). Stem cells were maintained on growth factor reduced Geltrex (Gibco) in E8 media with daily media exchange.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy

Huehnchen¹,

Schinke²,

Bangemann³

et al. 2022

JCI Insight

View full text Add to dashboard Cite

Background: Paclitaxel chemotherapy frequently induces dose-limiting sensory axonal polyneuropathy. As sensory symptoms are challenging to assess objectively in clinical routine, an easily accessible biomarker for chemotherapy-induced polyneuropathy (CIPN) holds the potential to improve early diagnosis. Here, we describe neurofilament light chain (NFL), a marker for neuroaxonal damage, as translational surrogate marker for CIPN. Methods: NFL concentrations were measured in an in vitro model of CIPN, exposing induced pluripotent stem cell-derived sensory neurons (iPSC-DSN) to paclitaxel. Breast and ovarian cancer patients undergoing paclitaxel chemotherapy, breast cancer control patients without chemotherapy and healthy controls were recruited in a cohort study and examined before chemotherapy (V1) and after 28 weeks (V2, after chemotherapy). CIPN was assessed by the validated Total Neuropathy Score reduced, which combines patient-reported symptoms with data from clinical examinations. Serum NFL (NFLs) concentrations were measured at both visits with single molecule array technology (SIMOA).Results: NFL is released from iPSC-DSN upon paclitaxel incubation in a dose-and time-dependent manner and inversely correlates with iPSC-DSN viability. NFLs strongly increased in paclitaxel-treated patients with CIPN, but not in chemotherapy patients without CIPN or controls, resulting in an 86 % sensitivity and 87 % specificity.A NFLs increase of +36 pg/ml from baseline was associated with a predicted CIPN probability of >0.5. Conclusion:NFLs correlates with CIPN development and severity, which may guide neurotoxic chemotherapy in the future.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy

Huehnchen¹,

Schinke²,

Bangemann³

et al. 2022

JCI Insight

View full text Add to dashboard Cite

show abstract

“…Detailed methods, testing for the absence of the reprogramming vectors, FACS staining and analysis for pluripotency markers, and short tandem repeat analysis were done as described ( Hennig et al, 2019). Methods of SNP analysis for karyotyping, and mycoplasma screening were published (Cernoch et al, 2021). Screening of donor cells for HIV1/2 and Hepatitis B/C was done by commercial diagnostic laboratories on a routine basis.…”

Section: Testing the Ipsc Clones For Genotype Residual Vectors Dna Pl...mentioning

confidence: 99%

Generation of two mother–child pairs of iPSCs from maternally inherited Leigh syndrome patients with m.8993 T > G and m.9176 T > G MT-ATP6 mutations

et al. 2023

Self Cite

View full text Add to dashboard Cite

Generation of 20 human induced pluripotent stem cell lines from patients with focal segmental glomerulosclerosis (FSGS)

Cited by 2 publications

References 3 publications

Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy

Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy

Generation of two mother–child pairs of iPSCs from maternally inherited Leigh syndrome patients with m.8993 T > G and m.9176 T > G MT-ATP6 mutations

Contact Info

Product

Resources

About